MASAC supports participation in AIDS clinical trials by HIV-infected persons with hemophilia and other bleeding disorders. MASAC specifically supports the optimization of inclusion criteria to allow such individuals to participate in AIDS clinical trials. MASAC also supports development of studies to evaluate treatment of other complications that affect the bleeding disorders population such as HCV co-infection. Reference: Research Priorities in Hemophilia: HCV and HIV Disease, A Blueprint for Action. White Paper, National Hemophilia Foundation, New York, April 1999.